# A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

> **NCT00437268** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Tumor

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** irinotecan
- **DRUG:** cetuximab

## Key facts

- **NCT ID:** NCT00437268
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00437268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00437268, "A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00437268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*